Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islet Transplantation with Rituximab (CIT-05)
NCT00468442Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2006
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Insulin independence at 75 days. Started Nov 2006; status: terminated.
02
Drugs
rituximab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00468442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468442.